| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/13543784.2012.729819 |
| P698 | PubMed publication ID | 23013434 |
| P2093 | author name string | Lindsay M Oberman | |
| P2860 | cites work | Alterations of GABAergic signaling in autism spectrum disorders | Q21296802 |
| The Autistic Neuron: Troubled Translation? | Q22252314 | ||
| The neurology of autism spectrum disorders | Q24612945 | ||
| Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis | Q24648897 | ||
| A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. | Q24654933 | ||
| Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism | Q27329063 | ||
| Minicolumnar pathology in autism | Q28200704 | ||
| The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1 | Q28585945 | ||
| Model of autism: increased ratio of excitation/inhibition in key neural systems | Q29547530 | ||
| Neocortical excitation/inhibition balance in information processing and social dysfunction | Q29616196 | ||
| Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes | Q29616326 | ||
| Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila | Q33323032 | ||
| Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP. | Q33685348 | ||
| Neuronal density and architecture (Gray Level Index) in the brains of autistic patients. | Q33961521 | ||
| Comorbid psychopathology with autism spectrum disorder in children: an overview | Q33996670 | ||
| Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. | Q34157712 | ||
| Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome | Q34400166 | ||
| Increased serum levels of glutamate in adult patients with autism. | Q34550517 | ||
| Pharmacological reversal of synaptic plasticity deficits in the mouse model of fragile X syndrome by group II mGluR antagonist or lithium treatment | Q34631614 | ||
| Fragile x syndrome and autism: from disease model to therapeutic targets | Q35187269 | ||
| Alterations in GABAergic biomarkers in the autism brain: research findings and clinical implications | Q35303054 | ||
| Psychometric study of the Aberrant Behavior Checklist in Fragile X Syndrome and implications for targeted treatment | Q35791185 | ||
| TARGETED TREATMENTS IN AUTISM AND FRAGILE X SYNDROME | Q36399716 | ||
| Inactivation of the maternal fragile X gene results in sensitization of GABAB receptor function in the offspring | Q37153560 | ||
| Syndromic autism: causes and pathogenetic pathways | Q37582801 | ||
| Pathways to drug development for autism spectrum disorders | Q37972081 | ||
| Suppressed GABAergic inhibition as a common factor in suspected etiologies of autism | Q43671998 | ||
| Involvement of reelin and Cajal-Retzius cells in the developmental formation of vertical columnar structures in the cerebral cortex: evidence from the study of mouse presubicular cortex | Q44129414 | ||
| Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices | Q44174105 | ||
| Plasma amino acid levels in children with autism and their families | Q44412272 | ||
| Complex effects of mGluR5 antagonism on sociability and stereotypic behaviors in mice: possible implications for the pharmacotherapy of autism spectrum disorders | Q44968387 | ||
| Increased GABA(B) receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures | Q46058214 | ||
| Suppression of LTP-like plasticity in human motor cortex by the GABAB receptor agonist baclofen | Q48247274 | ||
| Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice | Q48569575 | ||
| GABA(B)-mediated presynaptic inhibition of excitatory transmission and synaptic vesicle dynamics in cultured hippocampal neurons | Q48819847 | ||
| Selective serotonin re-uptake inhibitors for the treatment of perseverative and maladaptive behaviours of people with intellectual disability. | Q50301551 | ||
| Serotonin and amino acid content in platelets of autistic children. | Q50305020 | ||
| The neurochemical basis for the treatment of autism spectrum disorders and Fragile X Syndrome. | Q50312684 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | autism | Q38404 |
| pharmacology | Q128406 | ||
| autism spectrum disorder | Q1436063 | ||
| P304 | page(s) | 1819-1825 | |
| P577 | publication date | 2012-09-26 | |
| P1433 | published in | Expert Opinion on Investigational Drugs | Q5421208 |
| P1476 | title | mGluR antagonists and GABA agonists as novel pharmacological agents for the treatment of autism spectrum disorders | |
| P478 | volume | 21 |
| Q92258414 | Anatomy and Physiology of Metabotropic Glutamate Receptors in Mammalian and Avian Auditory System |
| Q30841272 | Epilepsy and intellectual disability linked protein Shrm4 interaction with GABABRs shapes inhibitory neurotransmission |
| Q28391720 | GABAB Receptor Agonist R-Baclofen Reverses Social Deficits and Reduces Repetitive Behavior in Two Mouse Models of Autism |
| Q27013583 | GABAergic signaling as therapeutic target for autism spectrum disorders |
| Q21129398 | Gluten- and casein-free dietary intervention for autism spectrum conditions |
| Q26744037 | Identification and Treatment of Pathophysiological Comorbidities of Autism Spectrum Disorder to Achieve Optimal Outcomes |
| Q35721772 | Metabotropic Glutamate Receptors: MODULATORS OF CONTEXT-DEPENDENT FEEDING BEHAVIOUR IN C. ELEGANS |
| Q30363783 | Metabotropic glutamate receptors in auditory processing. |
| Q39269008 | Neurobiological bases of autism-epilepsy comorbidity: a focus on excitation/inhibition imbalance |
| Q38977281 | Pharmaceuticals and Stem Cells in Autism Spectrum Disorders: Wishful Thinking? |
| Q88184890 | Probiotic treatment reduces the autistic-like excitation/inhibition imbalance in juvenile hamsters induced by orally administered propionic acid and clindamycin |
| Q41060924 | Sensitivity of the modified Children's Yale-Brown Obsessive Compulsive Scale to detect change: Results from two multi-site trials |
| Q58780865 | Social Skills Deficits in Autism Spectrum Disorder: Potential Biological Origins and Progress in Developing Therapeutic Agents |
| Q64071039 | The Role of Metabotropic Glutamate Receptors in Social Behavior in Rodents |
| Q38162501 | The need for a comprehensive molecular characterization of autism spectrum disorders |
| Q37288082 | The neuropathology of autism |
| Q28387385 | Therapeutic Effect of a Synthetic RORα/γ Agonist in an Animal Model of Autism |
| Q42096144 | Transcranial magnetic stimulation (TMS) therapy for autism: an international consensus conference held in conjunction with the international meeting for autism research on May 13th and 14th, 2014. |
| Q28300252 | Use of transcranial magnetic stimulation in autism spectrum disorders |
| Q47812079 | What Have Proteomic Studies Taught Us About Novel Drug Targets in Autism? |
Search more.